Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07413133 | A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers | PHASE1 | ACTIVE NOT_RECRUITING | 40 | — | — | Feb 11, 2026 | Jun 1, 2026 | Apr 28, 2026 | 2 | United States |
| NCT07141199 | A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers | PHASE1 | COMPLETED | 24 | — | — | Sep 2, 2025 | Mar 23, 2026 | Apr 28, 2026 | 1 | United States |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-8736.
Tmax of ABBV-8736.
AUClast of ABBV-8736.
AUCinf of ABBV-8736.
β of ABBV-8736.
t1/2 of ABBV-8736.
CL of ABBV-8736.
Cmax of ABBV-8736.
Tmax of ABBV-8736.
AUCtau of ABBV-8736.
Ctrough of ABBV-8736.
β of ABBV-8736.
t1/2 of ABBV-8736.
CL for IV dosing.
Incidence and concentrations of ADAs. Neutralizing ADAs (NAb) may be evaluated.
| Arm | Type | Description |
|---|---|---|
| Arm 1: Intravenous (IV) ABBV-8736 | EXPERIMENTAL | Participants will receive IV ABBV-8736 on Day 1. |
| Arm 2: Subcutaneous (SC) ABBV-8736 | EXPERIMENTAL | Participants will receive SC ABBV-8736 on Day 1. |
| Group 1: Dose A of ABBV-8736 | EXPERIMENTAL | Participants will receive intravenous (IV) ABBV-8736 dose A every 2 weeks for a total of 3 doses. |
| Group 1: Dose A of ABBV-8736 Placebo | PLACEBO_COMPARATOR | Participants will receive IV ABBV-8736 placebo dose A every 2 weeks for a total of 3 doses. |
| Group 2: Dose B of ABBV-8736 | EXPERIMENTAL | Participants will receive IV ABBV-8736 dose B every 2 weeks for a total of 3 doses. |
| Group 2: Dose B of ABBV-8736 Placebo | PLACEBO_COMPARATOR | Participants will receive IV ABBV-8736 placebo dose B every 2 weeks for a total of 3 doses. |
| Name | Type | Description |
|---|---|---|
| ABBV-8736 | DRUG | Intravenous Injection |
| Placebo | DRUG | IV Infusion |
Inclusion Criteria: * Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters. * Body weight \>= 35 kg. * A condition of general good health, based upon the results of a medical hi...